Kardi Ai Raises CZK 130M Series A at CZK 600M to Expand AI ECG Monitoring

Kardi Ai announced on November 11, 2026 that it raised CZK 130 million in a Series A led by German health-technology venture fund Callisto Health, giving the Czech startup a post-round valuation of CZK 600 million, according to the company’s release.

The capital is earmarked for further expansion in Europe and Asia and for models intended to estimate the risk of cardiac arrhythmias. Kardi Ai describes the financing as the largest investment round to date among Czech medtech startups.

The Seed Starter programs of Česká spořitelna and Slovenská sporiteľňa also participated, alongside BrightCap Ventures, Purple Ventures, DEPO Ventures and Garage Angels. Purple Ventures led Kardi Ai’s seed round in 2023, and BrightCap Ventures led its pre-seed round in 2022.

How the Monitoring System Works

Kardi Ai combines a sports chest strap containing an electrocardiogram (ECG) sensor, a mobile application and AI analysis of the recordings. Users can wear the device during ordinary daily activities, view results and make them available to a physician. The system does not itself establish a diagnosis. It supplies information for decisions about further care. The company says longer recordings can help capture intermittently occurring arrhythmias that a short examination may miss.

Kardi Ai reports working with more than 70 hospitals and more than 20 corporate and employee-benefit partners in Czechia. Its technology has more than 6,000 users; approximately one-quarter received an alert about a possible arrhythmia during long-term monitoring, and more than 500 detections were assessed as critical.

Market Entries Across Europe and Asia

Kardi Ai operates in Czechia, Slovakia, Poland, Romania and Bulgaria. It is preparing a German launch after completing pilot projects. In Slovakia, the company reports working with more than 20 physicians, mainly cardiologists, after entering through a local distributor.

Outside Europe, Kardi Ai says India’s drug regulator, CDSCO, issued an MD-15 import licence covering its hardware and software in July 2026. The Indian entry is planned to begin in Hyderabad, where discussions with healthcare partners and commercial and logistics preparations are continuing. Operations are planned for the fourth quarter of 2026.

Kardi Ai reports holding a medical-device registration certificate from the UAE Ministry of Health and Prevention and is preparing market entry there. Medical-device approval in Singapore remains in progress. The company plans to use Singapore as an entry point to Southeast Asia, with the Philippines, Indonesia and Vietnam identified as subsequent target markets.

Predictive Models Require Validation

Kardi Ai plans for its predictive models to use data from several measurements to estimate arrhythmia risk, extending the current technology beyond long-term monitoring and evaluation of heart rhythm. The models remain in development and must undergo expert validation and the applicable regulatory approval process before use in healthcare practice.

Chief executive Vlastimil Hrabal said the development goal is to warn of elevated risk before an arrhythmia manifests, with the new capital supporting validation across global markets and different patient demographics.

Callisto Health managing director Stefan Eckhardt said the product combines a certified medical device, ease of use and medical benefit, and noted its existing use in routine practice in Central and Eastern Europe.

The financing ties international expansion to a distinct development hurdle. Market launches can build on the existing monitoring system, while clinical use of the proposed earlier-warning models depends on completing validation and regulatory approval.